Shaperon Inc. (KOSDAQ:378800)

Market Cap	91.05B
Revenue (ttm)	179.38M +96.6%
Net Income	-14.59B
EPS	-541.21
Shares Out	46.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,081,049
Average Volume	1,307,587
Open	1,973.00
Previous Close	1,932.00
Day's Range	1,860.00 - 1,986.00
52-Week Range	1,580.00 - 4,120.00
Beta	0.01
RSI	57.34
Earnings Date	Nov 14, 2025

About Shaperon

Shaperon Inc., a clinical stage biotech company, develops novel inflammasome inhibitors targeting immune-mediated inflammatory disorders with high unmet medical needs and nanobody therapeutics. It offers NuGel, a gel type atopic dermatitis drug candidate in Phase 2 clinical trials; and NuSepin, an IV injection form of HY209 in Phase 2 clinical trials for use in the treatment of systemic inflammatory response syndrome. The company also provides Oral HY209, an oral formulation of HY209 for use in the treatment of neuroinflammatory diseases; and H...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 378800

Financial Performance

In 2024, Shaperon's revenue was 17.70 million, a decrease of -91.77% compared to the previous year's 215.25 million. Losses were -14.90 billion, 20.2% more than in 2023.